244 related articles for article (PubMed ID: 24043770)
1. Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.
Haj-Yahya M; Fauvet B; Herman-Bachinsky Y; Hejjaoui M; Bavikar SN; Karthikeyan SV; Ciechanover A; Lashuel HA; Brik A
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17726-31. PubMed ID: 24043770
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
Chen H; Zhao YF; Chen YX; Li YM
ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
[TBL] [Abstract][Full Text] [Related]
3. Breaking the limits of artificial ubiquitination.
Putyrski M; Dikic I
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17606-7. PubMed ID: 24143812
[No Abstract] [Full Text] [Related]
4. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
Schmid AW; Fauvet B; Moniatte M; Lashuel HA
Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418
[TBL] [Abstract][Full Text] [Related]
5. The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.
Al-Mansoori KM; Hasan MY; Al-Hayani A; El-Agnaf OM
Curr Alzheimer Res; 2013 Jul; 10(6):559-68. PubMed ID: 23899170
[TBL] [Abstract][Full Text] [Related]
6. Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.
Meier F; Abeywardana T; Dhall A; Marotta NP; Varkey J; Langen R; Chatterjee C; Pratt MR
J Am Chem Soc; 2012 Mar; 134(12):5468-71. PubMed ID: 22404520
[TBL] [Abstract][Full Text] [Related]
7. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
He S; Wang F; Yung KKL; Zhang S; Qu S
ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
[TBL] [Abstract][Full Text] [Related]
8. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Effects of O-GlcNAc Modifications in Parkinson's Disease Using Semisynthetic α-Synuclein.
Galesic A; Pratt MR
Methods Mol Biol; 2020; 2133():313-326. PubMed ID: 32144674
[TBL] [Abstract][Full Text] [Related]
10. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death.
Lee JT; Wheeler TC; Li L; Chin LS
Hum Mol Genet; 2008 Mar; 17(6):906-17. PubMed ID: 18065497
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
13. Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.
Redeker V; Pemberton S; Bienvenut W; Bousset L; Melki R
J Biol Chem; 2012 Sep; 287(39):32630-9. PubMed ID: 22843682
[TBL] [Abstract][Full Text] [Related]
14. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
15. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the Role of Site-Specific Nitration of α-Synuclein in the Pathogenesis of Parkinson's Disease via Protein Semisynthesis and Mutagenesis.
Burai R; Ait-Bouziad N; Chiki A; Lashuel HA
J Am Chem Soc; 2015 Apr; 137(15):5041-52. PubMed ID: 25768729
[TBL] [Abstract][Full Text] [Related]
18. How is alpha-synuclein cleared from the cell?
Stefanis L; Emmanouilidou E; Pantazopoulou M; Kirik D; Vekrellis K; Tofaris GK
J Neurochem; 2019 Sep; 150(5):577-590. PubMed ID: 31069800
[TBL] [Abstract][Full Text] [Related]
19. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway.
Tofaris GK; Kim HT; Hourez R; Jung JW; Kim KP; Goldberg AL
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17004-9. PubMed ID: 21953697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
